Rhea-AI Summary
Retension Pharmaceuticals (RTSN) priced its upsized initial public offering at $12.00 per share, with all shares offered by the company.
The offering comprises 3,750,000 common shares and is expected to generate $45.0 million in gross proceeds before underwriting discounts, commissions and other offering expenses. Underwriters have a 30-day option to buy up to 562,500 additional shares. Trading on the Nasdaq Capital Market is expected to begin October 9, 2026, with closing expected on or about October 13, 2026. Retension intends to use net proceeds and existing cash to complete RTN-001’s Phase 2b trial in uncontrolled hypertension and prepare for, support and advance its planned Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags